Since 2014, Certara’s customers received 90% of FDA new drug approvals
Drug discovery and development is a long and expensive process, which often times results in more failures than successes. At Certara, we anticipate and address your critical drug discovery and development risks and decisions using biosimulation and tech-enable services.
90 percent of new drug approvals by the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Review (CDER) were received by Certara’s customers in 2021, excluding diagnostic agents. This is the 8th consecutive year that Certara’s customers, who use the Company’s biosimulation software and technology-driven services, have had novel drugs approved by the FDA in a wide range of therapeutic indications, from oncology to rare diseases.
Unmatched expertise to empower your drug development team
From clinical pharmacology and pharmacometrics to regulatory and market access support, we have over 650 leading experts across the globe who are dedicated to achieving your goals.
Enable well-informed decisions faster with cutting-edge technology
Scientists and regulators rely on our industry-leading software to inform complex decisions throughout the entire drug discovery and development process.
Enter for your chance to win a pair of Apple AirPods Pro ear buds!
Disclaimer: Winner will be drawn and contacted on Monday, December 5th. By entering this drawing, I agree to be contacted by Certara.